Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

March 31, 2001

Conditions
Pancreatic Cancer
Interventions
DRUG

cisplatin

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

Trial Locations (19)

1000

Institut Jules Bordet, Brussels

1070

Hopital Universitaire Erasme, Brussels

35340

Dokuz Eylul University School of Medicine, Izmir

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

58095

Marien Hospital, Hagen

B-3000

U.Z. Gasthuisberg, Leuven

Unknown

National Cancer Institute of Egypt, Cairo

F-92104

CHU Ambroise Pare, Boulogne-Billancourt

F-94805

Institut Gustave Roussy, Villejuif

D-92224

Klinikum St. Marien, Amberg

D-45122

Universitaetsklinik und Strahlenklinik - Essen, Essen

D-60590

Klinikum der J.W. Goethe Universitaet, Frankfurt

D-20099

Hermann-Holthusen Institute for Radiotherapy, Hamburg

D-30625

Medizinische Hochschule Hannover, Hanover

D-01844

Praxis Innere Medizin, Neustadt

D-89081

Klinikum der Universitaet Ulm, Ulm

6043 CV

Saint Laurentius Ziekenhuis, Roermond

02-781

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw

G11 6NT

Beatson Oncology Centre, Glasgow

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00004884 - Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter